Innoviva has filed a patent for a compound represented by Structural Formula (A) and its pharmaceutically acceptable salt. The patent also includes a pharmaceutical composition containing the compound and its therapeutic use. GlobalData’s report on Innoviva gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Innoviva, human telomerase RT biomarker was a key innovation area identified from patents. Innoviva's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230122651A1) describes a compound represented by Structural Formula (A). The compound has various structural variations, with different substituents and functional groups. The patent claims cover these different variations and their use in pharmaceutical compositions and methods for treating or preventing infections or colonization in subjects.
The compound described in the patent has a wide range of potential applications in the field of medicine. It can be represented by different structural formulas, depending on the specific substituents and functional groups present. The patent claims cover various specific variations of the compound, including those where R1 is hydrogen or a (C1-C4)alkyl, and R2 is selected from (C1-C7)alkyl, (C3-C6)cycloalkyl(C1-C4)alkyl, (C1-C7)alkoxy(C1-C4)alkyl, phenyl, phenyl(C1-C4)alkyl, (C3-C6)cycloalkyl, and halo(C1-C4)alkyl. These variations can have additional substituents, such as (C1-C4)alkyl, halo, (C1-C4)alkoxy, (C1-C4)alkoxy(C1-C4)alkyl, —CN, halo(C1-C4)alkyl, and halo(C1-C4)alkoxy.
The patent claims also cover variations where R1 and R2 taken together with the nitrogen atom form a monocyclic or bicyclic heteroaryl, or a monocyclic, fused bicyclic, bridged bicyclic, or spiro bicyclic heterocycle. These heterocycles can contain additional heteroatoms such as N, O, and S, and can be substituted with (C1-C4)alkyl, halo, —OH, (C1-C4)alkoxy, (C1-C4)alkylthio, (C1-C4)alkylsulfinyl, (C1-C4)alkylsulfonyl, (C1-C4)alkoxy(C1-C4)alkyl, and —N(R3)(R4). Specific examples of these heterocycles include azetidine, pyrrolidine, morpholine, piperidine, octahydrocyclopenta[c]pyrrol, isoindoline, and azabicyclo[3.1.0]hexane.
The patent claims also include pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier or diluent, as well as methods for treating or preventing infections or colonization in subjects by administering an effective amount of the compound or its salt. The infections can be caused by Gram-positive or Gram-negative organisms.
In summary, the filed patent describes a compound with various structural variations and its use in pharmaceutical compositions and methods for treating or preventing infections or colonization. The compound has potential applications in the field of medicine and can be represented by different structural formulas depending on the specific substituents and functional groups present. The patent claims cover these different variations and their use in specific applications.
To know more about GlobalData’s detailed insights on Innoviva, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
